Vir Biotechnology, Inc. (VIR) has a consensus analyst rating of Buy, based on 12 analysts covering the stock. Of those, 10 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for VIR is $21.29, representing a +111.8% upside from the current price of $10.05. Price targets range from a low of $18.00 to a high of $30.00.
